Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80188
Name chronic myelomonocytic leukemia
Definition A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia chronic leukemia chronic myelomonocytic leukemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01773395 Phase II Busulfan + Fludarabine + Methotrexate + Tacrolimus Busulfan + Fludarabine + GVAX + Methotrexate + Tacrolimus GVAX vs. Placebo for MDS/AML After Allo HSCT Active, not recruiting USA 0
NCT01787487 Phase II Azacitidine + Ruxolitinib Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm Recruiting USA 0
NCT02193958 Phase Ib/II FF-10501-01 Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Completed USA 0
NCT02268253 Phase II Tagraxofusp-erzs Tagraxofusp (SL-401) in Patients With CMML or MF Recruiting USA | CAN 0
NCT02530034 Phase I Hu8F4 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Recruiting USA 0
NCT02546284 Phase I LAM-003 Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) Completed USA 0
NCT02717884 Phase Ib/II Cytarabine + Tranylcypromine + Tretinoin Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) (TRANSATRA) Recruiting 1
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma Recruiting USA 0
NCT02749708 Phase Ib/II IRX5183 Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Terminated USA 0
NCT02841540 Phase I H3B-8800 A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Recruiting USA 3
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting USA 0
NCT03047993 Phase Ib/II Azacitidine + Telaglenastat Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Recruiting USA 0
NCT03263637 Phase I AZD4573 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Recruiting 4
NCT03268954 Phase III Azacitidine + MLN4924 Azacitidine Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER) Active, not recruiting USA | CAN 18
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Active, not recruiting USA 0
NCT03306264 Phase III Decitabine Decitabine and Cedazuridine Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML Recruiting USA | CAN 8
NCT03326921 Phase I Fludarabine HA-1 TCR T cells HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Recruiting USA 0
NCT03358719 Phase I Decitabine + Nivolumab + Poly ICLC + Rasdegafusp alfa DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT03383575 Phase II Azacitidine + Enasidenib Enasidenib Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Active, not recruiting USA 0
NCT03386513 Phase I IMGN632 Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies Recruiting USA 3
NCT03404193 Phase II Decitabine + Venetoclax Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome Recruiting USA 0
NCT03404726 Phase I BAY2402234 A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies Terminated USA 1
NCT03515512 Phase I Enasidenib IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Active, not recruiting USA 0
NCT03564821 Phase I Ivosidenib IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Recruiting USA 0
NCT03613532 Phase I Busulfan + Fludarabine + Venetoclax Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN Recruiting USA 0
NCT03614728 Phase I Azacitidine + GSK3326595 GSK3326595 Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Recruiting USA | CAN 0
NCT03670966 Phase Ib/II BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome Recruiting USA 0
NCT03722407 Phase II Ruxolitinib Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion Recruiting USA 0
NCT03746041 Phase I Abaloparatide + Bevacizumab A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes Recruiting USA 0
NCT03770429 Phase I Ceralasertib AZD6738 for Patients With Progressive MDS or CMML Recruiting USA 0
NCT03807063 Phase I Rimiducid BPX-501 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Withdrawn USA 0
NCT03814005 Phase I Azacitidine + MLN4924 A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic Impairment Recruiting USA 1
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting USA 0
NCT03896269 Phase I CPX-351 CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Unknown status USA 0
NCT03912064 Phase I Ipilimumab A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Recruiting USA 0
NCT04016116 Phase II Pembrolizumab + Ruxolitinib Pembrolizumab Dual PD-1 and JAK2 Inhibition in Hematological Malignancies Withdrawn USA 0
NCT04041050 Phase I Navitoclax Navitoclax + Ruxolitinib A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm Recruiting USA 7
NCT04139434 Phase I LP-108 Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT04146038 Phase II Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Recruiting USA 0
NCT04160052 Phase Ib/II Azacitidine + Venetoclax Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome Recruiting USA 0
NCT04239157 Phase II Azacitidine + Canakinumab Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04256317 Phase III ASTX030 ASTX030 + Azacitidine ASTX030 + Azacitidine + Cedazuridine A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML Recruiting USA 0
NCT04264806 Phase II ARGX-110 + Azacitidine Azacitidine A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) Withdrawn 11
NCT04266301 Phase III Azacitidine Azacitidine + Sabatolimab Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2) Recruiting USA | CAN 32
NCT04372433 Phase I IO-202 IO-202 as Monotherapy in Patients in AML and CMML Recruiting USA 0
NCT04409639 Phase II Cobimetinib Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO) Recruiting USA 0
NCT04487106 Phase II Azacitidine + Trametinib + Venetoclax Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04493138 Phase Ib/II Azacitidine + Quizartinib Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Recruiting USA 0
NCT04522895 Phase II Enasidenib IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT Recruiting 1
NCT04550442 Phase Ib/II Azacitidine + Venetoclax Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04655755 Phase Ib/II Decitabine and Cedazuridine + Venetoclax Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04708054 Phase II Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome Not yet recruiting USA 0
NCT04730258 Phase Ib/II CFI-400945 CFI-400945 + Decitabine Azacitidine + CFI-400945 A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML (TWT-202) Recruiting USA 0
NCT04734990 Phase Ib/II Azacitidine + Seclidemstat Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT05024994 Phase II E7820 A Study of E7820 in People With Bone Marrow (Myeloid) Cancers Recruiting USA 0
NCT05030675 Phase I Fostamatinib Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents Recruiting USA 0